Niagen Bioscience Announces Participation in Upcoming Investor Conferences

LOS ANGELES--(BUSINESS WIRE)--$NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences:

A.G.P. Virtual Consumer Showcase

• Virtual showcase offering consumer company management teams a platform to share their story with the investment community
• Location: Virtual
• Date: November 11 - 12, 2026
• Format: Fireside chat Thursday, November 12, 2026 at 3:00 p.m. ET
• Management: Rob Fried, CEO & Ozan Pamir, CFO
• Investors may register here

Southwest IDEAS Investor Conference

• Independent institutional investor conference for publicly traded companies and institutional investors
• Location: The Westin Irving Convention Center in Las Colinas, Irving, Texas
• Date: November 18 - 19, 2026
• Format: Presentation on Thursday, November 19, 2026 from 4:00 - 4:35 p.m. CT and one-on-one meetings
• Management: Rob Fried, CEO & Ozan Pamir, CFO

15th Annual ROTH Deer Valley Event

• Invite-only annual networking conference for institutional investors and select public/private company management teams.
• Location: Montage Deer Valley Park City, Utah
• Date: December 9 - 12, 2026
• Format: One-on-one meetings
• Management: Rob Fried, CEO

StoneX 15th Annual Discovery Conference 2026

• Emerging growth investor forum for institutional investors and select public and private emerging growth companies.
• Location: New York Athletic Club New York, New York
• Date: December 10, 2026
• Format: One-on-one meetings
• Management: Ozan Pamir, CFO

If you would like to schedule a one-on-one meeting with the Niagen management team during either conference, please contact your respective conference representative or email Niagen@KCSA.com.

For additional information on Niagen Bioscience, visit www.niagenbioscience.com.

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD+ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience^™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There’s a better way to age.

At the heart of its clinically tested product portfolio is Niagen^® (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD+ booster available. Niagen powers the Company’s consumer supplement, Tru Niagen^®, the number one NAD+ boosting oral supplement in the United States† (available at www.truniagen.com), and Niagen™ Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (www.niagenplus.com). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company’s wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a differentiated small molecule.

Niagen Bioscience’s robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at www.niagenbioscience.com, where copies of press releases, news, and financial information are regularly published.

^†Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)

Niagen Bioscience Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310.405.5227
kendall.knysch@niagenbio.com

Niagen Bioscience Investor Relations Contact:
Valter Pinto, Managing Director
KCSA Strategic Communications
212.896.1254
Niagen@kcsa.com